Related Experiment Video

Updated: Sep 9, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice

Mohamad B Moumneh1, Yasser Jamil1, Michael G Nanna2

  • 1Inova Center of Outcomes Research, 3300 Gallows Road, Falls Church, VA 22042, USA.

Current Treatment Options in Cardiovascular Medicine
|September 2, 2025
PubMed

Insights

Drug-coated balloons (DCBs) offer a valuable alternative to traditional treatments for coronary artery disease (CAD). They are effective for various conditions, including in-stent restenosis and small-vessel disease.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Percutaneous coronary intervention (PCI) and drug-eluting stents were standard for coronary artery disease (CAD).
  • Limitations like in-stent stenosis and increased bleeding risk prompted the development of drug-coated balloons (DCBs).

Purpose of the Study:

  • To review the role of drug-coated balloons (DCBs) in current coronary artery disease (CAD) management.
  • To focus on clinical indications and technical considerations for DCB use.
  • To incorporate insights from the International DCB Consensus Group.

Main Methods:

  • Review of current literature and consensus guidelines on DCB use in CAD.
  • Analysis of clinical indications and technical aspects of DCB application.
  • Synthesis of evidence supporting DCB efficacy in diverse patient populations.

Main Results:

  • Drug-coated balloons (DCBs) are established for treating in-stent restenosis, small-vessel disease, bifurcations, and high bleeding risk patients.
  • DCBs are also indicated for acute coronary syndromes and in diabetic patients.
  • Optimal outcomes require functional assessments, lesion preparation, and careful patient selection.

Conclusions:

  • Drug-coated balloons (DCBs) represent a significant advancement in coronary artery disease (CAD) management.
  • Ongoing innovations in DCB technology and further clinical trials are expected to broaden their application.
  • Effective use of DCBs necessitates meticulous procedural planning and patient selection for optimal drug delivery and reduced complications.
Abstract

Keywords:
Coronary artery diseaseDrug-coated balloonsPercutaneous coronary intervention

More Related Videos

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

6.9K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33